Spots Global Cancer Trial Database for A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Official Title: A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Study ID: NCT04945733
Interventions
Study Description
Brief Summary: The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center Hospital, Chuo-Ku, , Japan
National Cancer Center Hospital East, Kashiwa, , Japan
Saitama Cancer center, Kitaadachi-gun, , Japan
Niigata Cancer Center Hospital, Niigata, , Japan
Hokkaido University Hospital, Sapporo-shi, , Japan
Tohoku University Hospital, Sendai, , Japan
Osaka University Hospital, Suita-shi, , Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, , Japan
The Cancer Institute Hospital of JFCR, Tokyo, , Japan
Yokohama City University Medical Center, Yokohama, , Japan
Contact Details
Name: Janssen Pharmaceutical K.K., Japan Clinical Trial
Affiliation: Janssen Pharmaceutical K.K.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
